Mobility in Daily Life and Falls in Parkinson's Disease: Potential for Rehabilitation

November 4, 2026 updated by: Martina Mancini, Oregon Health and Science University

The goal of this intervention is to explore the effectiveness of a Turning Intervention (TURN-IT) to improve quality of turning in participants with Parkinson's Disease (PD). An unique exercise program has been developed - TURN-IT - in which participants practice exercises that focus on physiological constraints that impair turning ability, such as axial rigidity, narrow base of support, bradykinesia, and inflexible set-shifting. The 60 participants with PD and a history of falls in the previous 12 months, will be randomized into a 6-week, 3x/week, one-on-one TURN-IT group or No-Intervention Control group. This pilot intervention study will determine the number of subjects needed for a future clinical trial and will determine the sensitivity to change with rehabilitation our daily-life turning quality measures (such as, mean and variability of number of steps to turn, turn amplitude, turn velocity). The investigators predict that the TURN-IT program will improve turning in daily life enough to justify a larger clinical trial.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

55

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Oregon
      • Portland, Oregon, United States, 97239
        • Oregon Health & Science University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

55 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Diagnosis of idiopathic PD from movement disorders neurologist with the United Kingdom Brain Bank criteria of bradykinesia with 1 or more of the following - rest tremor, rigidity, and balance problems not from visual, vestibular, cerebellar or proprioceptive conditions
  2. Responsive to levodopa
  3. Hoehn & Yahr stages II-IV
  4. Age range 55-85 years old
  5. self-report of one or more falls in past 12 months
  6. willing and able to attend exercise intervention sessions at Oregon Health & Science University (OHSU) campus, and also refrain from changes in anti-parkinson medications and exercise levels.

Exclusion Criteria:

  1. Major musculoskeletal or neurological disorders, structural brain disease, epilepsy, acute illness or health history, other than PD
  2. no medical condition that precludes exercise
  3. Montreal Cognitive Assessment (MoCA) ≤ 21 or inability to follow directions
  4. excessive use of alcohol or recreational drugs
  5. recent change in medication
  6. inability to stand and walk for 2 minutes without an assistive device

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: TURN-IT group

Participants in the treatment group will attend supervised, 1-hour classes, 3 times per week for 6 weeks, one-on-one with the same exercise trainer, overseen by a physical therapist investigator.

Based on the exercise motor learning principles, participants spend 10-15 minutes at each Exercise Station that focuses on particular constraints of turning ability. The stations will focus on important underlying aspects of turning, such as weight-shifting and increasing axial rotation during functional turning tasks. Each station will be progressed across levels to make more challenging (such as adding a dual task). Initially participants will be supported in an overhead body-weight support system (ZeroG) to allow them to practice challenging exercises without the risk of falling.

No Intervention: No Intervention Control Group

Participants in this group will be tested at baseline and 6 weeks later. They will go about their normal daily life during the 6 week period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Variability in Number of Steps to Complete a Turn
Time Frame: 6 weeks

The coefficient of variation in the number of steps in a turn, averaged from daily monitoring, as measured at 6 weeks.

6 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Falls Efficacy Scale International
Time Frame: baseline and 6 weeks

The difference in the Falls Efficacy Scale, as measured at baseline and 6 weeks. The Falls Efficacy Scale is a 16 item self-administered questionnaire to assess fear of falling. Scores range 16-64 with higher score indicating more fear of falling.

baseline and 6 weeks
Prospective Fall Incidence
Time Frame: 52 weeks

Number of prospective falls recorded for 12 months starting from the end of intervention

52 weeks
Patient Global Impression of Change
Time Frame: 6 weeks

Question of participant's rating of mobility. Score range from 1-7 with 1-3 indicating improvement, 4 no change, and 5-7 worsening of mobility. Single score provided at the end of 6 week period.

6 weeks
Number of Steps to Complete a Turn
Time Frame: 6 weeks

The number of steps in a turning averaged from daily monitoring, as measured at 6 weeks.

6 weeks
Turn Peak Velocity
Time Frame: 6 weeks

Peak velocity of turns averaged from daily monitoring, as measured at 6 weeks.

6 weeks
Turn Angle Amplitude
Time Frame: 6 weeks

The peak size of turn angles averaged from daily monitoring, as measured at 6 weeks.

6 weeks
Turn Duration
Time Frame: 6 weeks

Time to complete turns averaged from daily monitoring, as measured at 6 weeks.

6 weeks
Variability of Double-support Time
Time Frame: 6 weeks

The coefficient of variation in time of double-support phase, as measured at 6 weeks.

6 weeks
Lateral Trunk Range
Time Frame: 6 weeks

The range of motion in the trunk during walking, in the lateral direction, as measured at 6 weeks.

6 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Mini-Balance Evaluation Systems Test
Time Frame: baseline and 6 weeks

The change in mini-Balance Evaluation Systems Test, a clinical measure of four balance domains-anticipatory, reactive, sensory, and dynamic gait, as measured at baseline and 6 weeks. Scores range from 0-28 with higher scores indicating worse balance.

baseline and 6 weeks
Clinical Global Impression of Change
Time Frame: 6 weeks

Question of clinician's rating of participant mobility. Score range from 1-7 with 1-3 indicating improvement, 4 no change, and 5-7 worsening of mobility. Single score provided at the end of 6 week period.

6 weeks
Change in Parkinson's Disease Questionnaire-39
Time Frame: baseline and 6 weeks

The difference in the Parkinson's disease questionnaire-39 (PDQ-39) - a 39 item self-report questionnaire to assess Parkinson's disease specific health related quality in eight domains of quality of life - as measured at baseline and 6 weeks. Each item scores from 0 (never) to 4 (always). Sub-scale scores and a Parkinson's Disease summary index (PDSI; sum of eight subsections/8) representing the global health-related quality of life will be calculated, with higher scores representing worse quality of life

baseline and 6 weeks
Change in Unified Parkinson's Disease Rating Scale, Part III
Time Frame: baseline and 6 weeks

Difference in the Unified Parkinson's Disease Rating Scale, Part III (UPDRS-III), as measured at baseline and 6 weeks.

The UPDRS-III is a clinical scale to assess severity of motor symptoms in Parkinson's disease. Each item is scored 0 (normal) to 4 (severe) with a score range from 0-132

baseline and 6 weeks
Change in Activities-Specific Balance Confidence Scale
Time Frame: baseline and 6 weeks

The difference in Activities-Specific Balance Confidence (ABC) Scale, as measured at baseline and 6 weeks.

The ABC Scale is a 16-item self-report scale that participants rate their confidence in performing daily activities. Score range from 0-100% with 0% meaning no confidence and 100% completely confident

baseline and 6 weeks
Stride Velocity
Time Frame: 6 weeks

Stride velocity during straight walking averaged from daily monitoring, as measured at 6 weeks.

6 weeks
Stride Length
Time Frame: 6 weeks

Stride length during straight walking averaged from daily monitoring, as measured at 6 weeks.

6 weeks
Cadence
Time Frame: 6 weeks

The number of straight walking steps taken per minute averaged from daily monitoring, as measured at 6 weeks.

6 weeks
Double Support Time
Time Frame: 6 weeks

The amount of time both feet were on the ground together during straight walking averaged from daily monitoring, as measured at 6 weeks.

6 weeks
Angle of Foot at Heel Strike
Time Frame: 6 weeks

The angle between the foot and the ground at heel strike during straight walking averaged from daily monitoring, as measured at 6 weeks.

6 weeks
Variability of Angle of Foot at Heel Strike
Time Frame: 6 weeks

Coefficient of variation of the angle between the foot and the ground at heel strike during straight walking averaged from daily monitoring, as measured at 6 weeks.

6 weeks
Number of Turns Per Hour
Time Frame: 6 weeks

The average number of turns per hour measured during daily monitoring at 6 weeks.

6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Fay Horak, PhD, PT, Oregon Health and Science University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 13, 2021

Primary Completion (Actual)

June 30, 2025

Study Completion (Actual)

July 1, 2026

Study Registration Dates

First Submitted

May 18, 2021

First Submitted That Met QC Criteria

May 18, 2021

First Posted (Actual)

May 21, 2021

Study Record Updates

Last Update Posted (Actual)

November 6, 2026

Last Update Submitted That Met QC Criteria

November 4, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • R01HD100383 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Upon reasonable request, we can share de-identified data related to study outcomes measures.

IPD Sharing Time Frame

Data would be available 6 months after the end of data collection. Data will be stored in our laboratory data repository and so will be available indefinitely.

IPD Sharing Access Criteria

Data will not be stored on a public website, however researchers may contact us for access to the data. We will send data electronically via a secure server.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.